Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Recurrence 1Lymphoma, Mantle-Cell 1Immunoblastic Lymphadenopathy 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Bortezomib 9Cyclophosphamide 7tanespimycin 4fludarabine phosphate 4Vorinostat 4Paclitaxel 4Filgrastim 4Carboplatin 4fludarabine 3Peripheral Blood Stem Cell Transplantation 3Lenalidomide 3Irinotecan 3Everolimus 3Etoposide 3Doxorubicin 3Dasatinib 3Azacitidine 3sargramostim 2romidepsin 2laromustine 2ixabepilone 2entinostat 2belinostat 2Whole-Body Irradiation 2Vincristine 2Topotecan 2Tacrolimus 2Radiotherapy 2Prednisone 2Pharmacogenomic Testing 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunoblastic Lymphadenopathy × glofitamab × Clear all
NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc.

Phase 1 Recruiting
255 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡